GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alexza Pharmaceuticals Inc (OTCPK:ALXA) » Definitions » Quality Rank

Alexza Pharmaceuticals (Alexza Pharmaceuticals) Quality Rank


View and export this data going back to 2006. Start your Free Trial

What is Alexza Pharmaceuticals Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Alexza Pharmaceuticals Quality Rank Related Terms

Thank you for viewing the detailed overview of Alexza Pharmaceuticals's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Alexza Pharmaceuticals (Alexza Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Alexza Pharmaceuticals Inc was incorporated in the state of Delaware on December 19, 2000 as FaxMed, Inc. In June 2001, it changed the name to Alexza Corporation and in December 2001 it became Alexza Molecular Delivery Corporation. In July 2005, it changed the name to Alexza Pharmaceuticals, Inc. It is a pharmaceutical company, engaged in the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. ADASUVE is its only approved product & there is one product candidate in active development, AZ-002 (Staccato alprazolam), which is being developed for the treatment of acute repetitive seizures, sometimes called cluster seizures or ARS. ADASUVE, or Staccato loxapine, and its product candidates are based on its proprietary technology, the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. Because of the particle size of the aerosol, the drug is quickly absorbed through the deep lung into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous, or IV, administration but with greater ease, patient comfort and convenience. The pharmaceutical and biotechnology industries are intensely competitive. Many pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations are actively engaged in research and development of products targeting the same markets as ADASUVE and its other product candidates. The names "Alexza Pharmaceuticals," "Alexza," "Staccato" and "ADASUVE" are trademarks of the Company. It helds 195 issued and allowed U.S. and international patents. The testing, manufacturing, labeling, advertising, promotion, distribution, export and marketing of the Company's product candidates are subject to extensive regulation by governmental authorities in the United States and other countries.
Executives
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Gordon Ringold director 325 EAST MIDDLEFIELD AVENUE, MOUNTAIN VIEW CA 94043
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Thomas Braxton King director, officer: President & CEO 91 JAMES AVENUE, ATHERTON CA 94027
Joseph L Turner director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Mark K Oki officer: Former SVP, CFO, Secretary C/O ALEXZA PHARMACEUTICALS INC, 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Robert A Lippe officer: EVP, Operations & COO C/O ALEXZA PHARMACEUTICALS, INC., 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
James V Cassella director, officer: Former EVP, R&D and CSO 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Samuel D Colella other: Former Director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Alan D Frazier director
Symphony Capital Gp, L.p. 10 percent owner, other: See Footnote 2 and Remarks C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Harri V Taranto 10 percent owner, other: See Footnote 2 and Remarks C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Symphony Gp, Llc 10 percent owner, other: See Footnote 2 and Remarks C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Symphony Capital Partners Lp 10 percent owner, other: See Footnote 2 and Remarks C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, NEW YORK NY 10022
Mark Kessel 10 percent owner, other: See Footnote 2 and Remarks 950 PARK AVE APT. 11A, NEW YORK NY 10028